Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)

• ClinicalTrials.gov Identifier: NCT00805935
• Recruitment Status: Completed
• First Posted: December 10, 2008
• Results First Posted: January 25, 2012
• Last Update Posted: January 27, 2012
• Sponsor: Ferring Pharmaceuticals
• Information provided by (Responsible Party): Ferring Pharmaceuticals

Tracking Information

• First Submitted Date: December 9, 2008
• First Posted Date: December 10, 2008
• Results First Submitted Date: November 28, 2011
• Results First Posted Date: January 25, 2012
• Last Update Posted Date: January 27, 2012
• Study Start Date: January 2009
• Actual Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: January 23, 2012)

Participants With Cycle Cancellation Due to Risk of Ovarian Hyperstimulation Syndrome (OHSS) Between Weeks 1 - 3 [ Time Frame: weeks 1-3 ]

A count of participants whose discontinuation was clearly documented on the study completion/termination form as cycle cancellation for risk of ovarian hyperstimulation syndrome (OHSS).

• Original Primary Outcome Measures (submitted: December 9, 2008): The primary endpoint for evaluation is rate of cycle cancellation due to risk of ovarian hyperstimulation syndrome (OHSS).

Current Secondary Outcome Measures (submitted: January 26, 2012)

• Number of Follicles Observed at Day 15 [ Time Frame: approximately day 15 ]
  The mean number of follicles observed in both ovaries at the last transvaginal ultrasound in the stimulation phase.
• Number of Oocytes Retrieved at Day 18 [ Time Frame: approximately day 18 ]
  The mean number of oocytes retrieved approximately 36 hours after hCG (Novarel®) administration and fertilized (by insemination or intra cytoplasmic sperm injection (ICSI)) according to site-specific procedures.
• Percentage of Oocytes Fertilized of the Total Number of Oocytes Retrieved [ Time Frame: approximately day 19 ]
  The fertilization rate for each participant was the percentage of the number of oocytes inseminated of the total number of oocytes retrieved.
• Number of Embryos Transferred at Three Stages of Development Before Implantation [ Time Frame: approximately day 24 ]
  The number of embryos, morulas and blastocysts transferred to the study participant on either day 3 or day 5 following fertilization. Embryos represent the earliest development stage and contain 2-8 cells. Morulas, the next stage, continued cellular cleavage results in a 16-30 cell solid sphere. Morula further develop into blastocyst, which contains 70-100 cells in a hollow spherical shape.
• Number of Embryos Frozen [ Time Frame: approximately day 24 ]
  The number of embryos that were not transferred but instead were frozen for future use.
• Percentage of Participants With Biochemical Pregnancy at Approximately Day 38 [ Time Frame: approximately day 38 (Day 14 post embryo transfer) ]
  Biochemical pregnancy is a positive β-hCG pregnancy test 12-14 days post embryo transfer.
• Percentage of Participants With Clinical Pregnancy at Week 7 [ Time Frame: approximately Day 52 ]
  Clinical pregnancy is the confirmation of the presence of intrauterine gestational sacs on pregnancy ultrasound examination.
• Percentage of Participants With Ongoing Pregnancy at Week 9 [ Time Frame: approximately Day 65 ]
  Clinical pregnancy is the confirmation of the presence of intrauterine gestational sacs on pregnancy ultrasound examination.
• Estradiol Levels at Day 6 [ Time Frame: Day 6 ]
  Estradiol monitoring during fertility therapy assesses follicular growth and is useful in monitoring the treatment. Blood tests sent to a central laboratory to obtain estradiol levels.
• Human Chorionic Gonadotropin (hCG) Levels at Day 6 [ Time Frame: Day 6 ]
  Blood tests were sent to a central laboratory to obtain hCG levels.
• Progesterone Levels at Human Chorionic Gonadotropin (hCG) Administration [ Time Frame: approximately day 16 ]
  Blood tests were sent to a central laboratory to obtain progesterone levels.
• Number of Live Births Resulting From the In Vitro Fertilization Process [ Time Frame: Approximately 10 months ]
  Number of live births resulting from the IVF process
• Participants With Treatment Emergent Adverse Events [ Time Frame: Week 1 to week12 ]
  Number of participants with adverse events (AEs) that started after first treatment. Severity used a three point scale: mild=awareness of signs/symptoms, but no disruption of usual activity moderate=event sufficient to affect usual activity (disturbing) severe=event causes inability to work or perform usual activities (unacceptable) Relatedness to study treatment used a four point scale: unrelated, unlikely, possible, probable. Seriousness refers to death, hospitalization, a life-threatening experience, persistent or significant disability/incapacity, or congenital anomaly.

• Original Secondary Outcome Measures (submitted: December 9, 2008): Secondary endpoints include pregnancy rates, clinical pregnancy and ongoing pregnancy
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)
• Official Title: A Multi-Center, Randomized, Open-Label Evaluation of MENOPUR® Versus FOLLISTIM® in Polycystic Ovarian Syndrome (PCOS) Patients
• Brief Summary: This multicenter, randomized, open-label exploratory study will be performed in approximately 200 polycystic ovary syndrome (PCOS) but otherwise healthy females undergoing in vitro fertilization (IVF). Each study center will follow its standard practice for in vitro fertilization (IVF) within the study parameters as noted in this protocol. The study centers will use marketed products purchased from Schraft's Pharmacy for all phases of the study (down-regulation, stimulation, ovulation induction, and luteal support). Subjects will be randomly assigned to highly purified menotropin (Menopur®) or follitropin beta (Follistim Pen®) for stimulation and progesterone vaginal insert (Endometrin®) or progesterone in oil for luteal support. Subjects will return to the study center for regular scheduled clinic visits as required per in vitro fertilization (IVF) protocol at the site and at specified times during the cycle (Stimulation Day 6, Day of human chorionic gonadotropin (hCG), and first serum pregnancy test) for estradiol (E2), progesterone (P4) and human chorionic gonadotropin (hCG) labs. All subjects will be required to complete a final study visit at completion of luteal support or negative serum pregnancy test following embryo transfer.
• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 4
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• Polycystic Ovarian Syndrome
• Infertility

Intervention

• Drug: Menotropin
  225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days.
  Other Name: Menopur®
• Drug: Progesterone vaginal insert
  100 mg inserted vaginally 2 or 3 times daily (BID or TID) (start on the day after oocyte retrieval) until 10 weeks gestation or confirmation of negative pregnancy test.
  Other Name: Endometrin®
• Drug: Follitropin beta
  225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days.
  Other Name: Follistim Pen®
• Drug: Progesterone in oil
  50 mg by intramuscular injection once per day, starting on the day after oocyte retrieval until 10 weeks gestation or confirmation of negative pregnancy test.
• Drug: leuprolide acetate
  Daily administration of 0.5mg of leuprolide acetate (depot formulations were not permitted) began on Day 21 following onset of menses, and then decreased to 0.25 mg when gonadotropin therapy was initiated.
  Other Name: Lupron

Study Arms

• Experimental: Menotropin/Progesterone vaginal insert

  Highly purified menotropin (Menopur®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.

  Progesterone vaginal insert (Endometrin®) 100 mg starts on the day following oocyte retrieval and continues for a total duration of 10 weeks or until a negative pregnancy test is obtained.

  Interventions:

  • Drug: Menotropin
  • Drug: Progesterone vaginal insert
  • Drug: leuprolide acetate
• Experimental: Menotropin/Progesterone in oil

  Menotropin (Menopur®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.

  Progesterone in oil 50 mg injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained.

  Interventions:

  • Drug: Menotropin
  • Drug: Progesterone in oil
  • Drug: leuprolide acetate
• Active Comparator: Follitropin beta/Progesterone vaginal insert

  Follitropin beta (Follistim Pen®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.

  Progesterone vaginal insert (Endometrin®) 50 mg injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained.

  Interventions:

  • Drug: Progesterone vaginal insert
  • Drug: Follitropin beta
  • Drug: leuprolide acetate
• Active Comparator: Follitropin beta/Progesterone in oil

  Follitropin beta (Follistim Pen®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.

  Progesterone in oil 50 mg injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained.

  Interventions:

  • Drug: Follitropin beta
  • Drug: Progesterone in oil
  • Drug: leuprolide acetate

• Publications *: Beltsos AN, Sanchez MD, Doody KJ, Bush MR, Domar AD, Collins MG. Patients' administration preferences: progesterone vaginal insert (Endometrin(R)) compared to intramuscular progesterone for Luteal phase support. Reprod Health. 2014 Nov 11;11:78. doi: 10.1186/1742-4755-11-78.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: January 23, 2012): 110
• Original Estimated Enrollment (submitted: December 9, 2008): 200
• Actual Study Completion Date: September 2010
• Actual Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

1. Pre-menopausal females between the ages of 18 and 42 years

2. Diagnosed with polycystic ovary syndrome (PCOS), using criteria adopted as the 2003 Rotterdam PCOS Consensus (2 out of 3, excluding other etiologies [congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome])

   • Oligo- or anovulation
   • Clinical and/or biochemical signs of hyperandrogenism
   • Polycystic ovaries
3. Body mass index (BMI) of 18-39
4. Early follicular phase (Day 3) follicle stimulating hormone (FSH) < 15 IU/L and estradiol (E2) within normal limits
5. Documented history of infertility (e.g., unable to conceive for at least one year, or for 6 months for women > 38 years of age, or bilateral tubal occlusion or absence, or male factor but excluding severe male factor requiring invasive or surgical sperm retrieval. Donor sperm may be used.)
6. Transvaginal ultrasound at screening consistent with findings adequate for assisted reproductive technology (ART) with respect to uterus and adnexa
7. Signed informed consent

Exclusion Criteria:

1. Gestational or surrogate carrier, donor oocyte
2. Presence of any clinically relevant systemic disease (e.g., uncontrolled thyroid or adrenal dysfunction, an organic intracranial lesion such as a pituitary tumor, insulin-dependent diabetes mellitus, uterine cancer)
3. Surgical or medical condition which, in the judgment of the Investigator or Sponsor, may interfere with absorption, distribution, metabolism, or excretion of the drugs to be used
4. Two or more previous failed in vitro fertilization (IVF) cycles or in vitro fertilization (IVF)/assisted reproductive technology (ART) failure due to a poor response to gonadotropins, defined as development of 2 mature follicles
5. History of recurrent pregnancy loss, defined as more than two clinical losses
6. Presence of abnormal uterine bleeding of undetermined origin
7. Current or recent substance abuse, including alcohol or smoking > 10 cigarettes per day
8. Refusal or inability to comply with the requirements of the Protocol for any reason, including scheduled clinic visits and laboratory tests
9. Participation in any experimental drug study within 30 days prior to Screening
10. Severe male factor requiring invasive or surgical sperm retrieval (e.g., microsurgical epididymal sperm aspiration [MESA], testicular sperm extraction [TESE])
11. Prior hypersensitivity to any of the protocol drugs

Sex/Gender

• Sexes Eligible for Study: Female

• Ages: 18 Years to 42 Years (Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT00805935
• Other Study ID Numbers: 2008-05
• Has Data Monitoring Committee: No
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: Ferring Pharmaceuticals
• Original Responsible Party: Emily Blake MD/Medical Director, Ferring Pharmaceuticals Inc
• Current Study Sponsor: Ferring Pharmaceuticals
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Study Director: Clinical Development Support; Ferring Pharmaceuticals

• PRS Account: Ferring Pharmaceuticals
• Verification Date: January 2012